Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients

• Published in: Annals of hematology Vol. 97; no. 9; pp. 1649 - 1661
• Main Authors: Allain, Eric P., Venzl, Karin, Caron, Patrick, Turcotte, Véronique, Simonyan, David, Gruber, Michaela, Le, Trang, Lévesque, Eric, Guillemette, Chantal, Vanura, Katrina
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-09-2018; Springer Nature B.V
• Subjects: Androgens; Hematology; Hormones; Leukemia; Medicine; Medicine & Public Health; Oncology; Original; Original Article; Steroids; Treatment-free survival; Chronic lymphocytic leukemia; Hormones; Mass spectrometry; Steroids
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-018-3356-z

Chronic lymphocytic leukemia (CLL) is not considered a hormone-regulated cancer although sex is a recognized risk factor with men more frequently diagnosed and developing progressive disease. We hypothesized that variable hormonal exposure may have a sexually dimorphic influence on treatment-free survival (TFS). In 156 CLL cases, we quantitatively profiled 29 circulating steroids (progesterone, adrenal precursors, androgens, estrogens, and catechol estrogens) as well as luteinizing hormone (LH) and follicle-stimulating hormone. Median TFS was shorter for men than that for women (80.7 vs. 135.0 months,
P
 = 0.033). Circulating hormone profiles in CLL patients were significantly different from those of healthy donors. In male CLL cases, higher LH levels were associated with shorter TFS (adjusted hazard ratio (HR
adj
) 2.11;
P
 = 0.004). In female CLL cases, high levels of the potent androgens testosterone and dihydrotestosterone and the sum of methoxy estrogens were associated with an improved TFS with HR
adj
values of 0.24 (
P
 = 0.007), 0.54 (
P
 = 0.023), and 0.31 (
P
 = 0.034), respectively. Reduced TFS was observed for women with CLL exhibiting high expression of the steroid-inactivating UGT2B17 enzyme. This study is the first to establish a link between the outcome of CLL patients, sex steroids, and pituitary hormones, revealing a sex-specific hormonal imbalance associated with disease progression.